γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL)

Inclusion Criteria: 1. Patients should sign informed consent form voluntarily. 2. Gender unlimited, age ≥ 18 years old. 3. Patients with relapsed or refractory B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphoblastic leukemia (CLL) and peripheral T cell lymphoma(PTCL) expect for γδT lymphoma. 4. Patients had an evaluable imaging lesion of at least greater than 1.5 cm (except CLL). 5. Eastern Cooperative Oncology Group (ECOG) Performance status 0-2. 6. Adequate bone marrow function as defined by：Absolute neutrophil count (ANC) \>1000/mm3；Absolute lymphocyte count (ALC) ≥300/mm3；Platelet ≥50000/mm3；Hemoglobin \>8.0g/dl. 7. Adequate end organ function as defined by: Total bilirubin ≤ 2 x upper limit of normal（ULN）; Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN; Creatinine ≤ 1.5 x ULN or any serum creatinine level associated with a measured or calculated creatinine clearance of ≥ 60ml/min. 8. Male and female of reproductive potential must agree to use birth control during the study and for at least 6 weeks post study. Exclusion Criteria: 1. Patients with history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT). 2. Active central nervous system (CNS) lymphoma; Patients with symptoms of CNS disease must undergo lumbar puncture and brain nuclear magnetic resonance to exclude CNS lymphoma. 3. Patients receiving chemotherapy within 2 weeks prior to γδT cell infusion, with the following exceptions: * Pretreatment chemotherapy prescribed by the protocol * In order to prevent CNS intrathecal chemotherapy (should be stopped 1 week before γδT cell therapy) * Other exploratory combined medications 4. Patients with systemic vasculitis, or with active or uncontrolled autoimmune diseases, as well as primary or secondary immunodeficiency diseases. 5. Active chronic hepatitis B or hepatitis C virus infection, active cytomegalovirus (CMV), EBV infection. 6. Major surgery that was evaluated by the investigator as unsuitable for inclusion within 4 weeks prior to screening. 7. History of other malignant tumors, with the following exceptions * Excisional non-melanoma (e.g. cutaneous basal cell carcinoma) * Cured situ carcinoma (e.g. cervical carcinoma) * Localized prostate cancer with radiotherapy or surgery * Patients with a history of malignant tumors, but the disease has been cured for ≥2 years 8. Patient's cardiac function meets any of the following conditions * Left ventricular ejection fraction (LVEF) ≤45% * Class III or IV heart failure according to the NYHA Heart Failure Classifications * QTcB\>450 msec * Other cardiac disease that investigators judge is not suitable for enrollment 9. History of epilepsy or other active central nervous system disorders. 10. Inoculated live vaccine within 6 weeks before screening. 11. Uncontrolled serious active infection (such as sepsis, bacteremia and fungemia). 12. Patients are allergic to cytokines. 13. Expected survival \< 12 weeks. 14. Participated in any other interventional clinical trial within three months. 15. Any situation that investigators believe the risk of the subjects is increased or results of the trial are disturbed.